Prospective, Multi-center, Randomized, Non-blind Trial to Assess the Efficacy and Safety of Moxifloxacin Versus Sulbactam/Ampicillin in the Treatment of Pulmonary Abscess and Aspiration Pneumonia
Sponsor study identifier
interventional
139
1 country
15
Study Start
February 2001
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
Not reported
Date not reportedStudy Completion
January 2005
Actual (reported)The purpose of this trial is to determine the efficacy and safety of Moxifloxacin in comparison to Sulbactam/Ampicillin in the treatment of pulmonary abscesses and aspiration pneumonia.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
January 2005
Actual (reported)Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
February 2001
Date type not reportedThis date has not been verified as actual or estimated.
January 2005
Actual (reported)January 8, 2010
Actual (reported)January 11, 2010
Actual (reported)Adverse events occuring after first application of study medication up to the test of cure visit for non-serious adverse events
Up to 30 days after end of treatment with study medication for serious adverse events
Clinical Response
Regulary doing i.v. treatment
Moxifloxacin, 400 mg iv, od, switch after 6 doses (6 days) to 400 mg Moxifloxacin oral, od
Sulbactam/Ampicillin, 3 g iv, tid, switch after 18 doses (6 days) to 750 mg Sulbactam/Ampicillin oral, bid
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
These entries preserve how the registry describes the intervention. Their treatment roles are shown separately from molecular identities.
Grouped treatment entry
Sulbactam/Ampicillin
The registry names several treatments. This does not confirm that participants received them together or that they form a single product.
View registry recordMannheim, Baden-Wurttemberg, 68167, Germany
Nuremberg, Bavaria, 90419, Germany
Regensburg, Bavaria, 93053, Germany
Treuenbrietzen, Brandenburg, 14929, Germany
Frankfurt am Main, Hesse, 60596, Germany
Hildesheim, Lower Saxony, 31134, Germany
Rotenburg (Wümme), Lower Saxony, 27356, Germany
Bayer Study Director
Bayer
139 participants (actual enrollment reported by the registry).
First Submitted
January 8, 2010
First Posted
January 11, 2010
Study Start
February 2001
Date type not reportedThis date has not been verified as actual or estimated.
Contact the study team to confirm eligibility.
Lüdenscheid, North Rhine-Westphalia, 58515, Germany
Oberhausen, North Rhine-Westphalia, 46045, Germany
Paderborn, North Rhine-Westphalia, 33098, Germany
Leipzig, Saxony, 04129, Germany
Magdeburg, Saxony-Anhalt, 39112, Germany
Lübeck, Schleswig-Holstein, 23538, Germany
Berlin, State of Berlin, 13353, Germany
Berlin, State of Berlin, 14165, Germany
Study Completion
January 2005
Actual (reported)Last Updated
January 11, 2010
Record last verified: 2010-01
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: